MYC is a major oncogenic driver of multiple myeloma (MM) and yet almost no therapeutic agents exist that target MYC in MM. Here we report that the let-7 biogenesis inhibitor LIN28B correlates with MYC expression in MM and is associated with adverse outcome. We also demonstrate that the LIN28B/let-7 axis modulates the expression of MYC, itself a let-7 target. Further, perturbation of the axis regulates the proliferation of MM cells in vivo in a xenograft tumor model. RNA-sequencing and gene set enrichment analyses of CRISPR-engineered cells further suggest that the LIN28/let-7 axis regulates MYC and cell cycle pathways in MM. We provide proof of principle for therapeutic regulation of MYC through let-7 with an LNA-GapmeR (locked nucleic acid-GapmeR) containing a let-7b mimic in vivo, demonstrating that high levels of let-7 expression repress tumor growth by regulating MYC expression. These findings reveal a novel mechanism of therapeutic targeting of MYC through the LIN28B/let-7 axis in MM that may impact other MYCdependent cancers as well.
INTRODUCTION
Multiple myeloma (MM), a tumor originating from plasma cells in the bone marrow (BM), has an annual incidence of 6.3 new cases per 100 000 individuals. 1 Despite the major advances in therapy for MM, it remains incurable and there are no targeted therapies for MM, in part, because of the lack of therapies that target specific oncogenes involved in the pathogenesis of the disease. Genomic events such as chromosomal translocations, copy number variation, somatic mutations and epigenetic modifications all contribute to gene deregulation of specific oncogenes or tumor suppressors during MM tumorigenesis. 2 Among those, MYC has a central role in the progression of the disease. Approximately twothirds of newly diagnosed patients harbor MYC activation, which correlates with adverse clinical outcome. 3 MYC activation is commonly driven by translocation or copy number gain of chromosome 8q24, which contains the MYC locus. 4, 5 Despite the dominant role of MYC in MM, there are very few therapeutic options targeting MYC. Previous studies have attempted to target MYC by using a bromodomain inhibitor to target BET proteins, which regulate MYC. 6, 7 The let-7 microRNA (miRNA) was originally discovered in Caenorhabditis elegans as a regulator of developmental timing and cell proliferation. 8 Let-7 expression increases as cells become more differentiated. In humans, let-7 miRNAs comprise a family of 12 members distributed over eight genomic loci 9 that are often repressed in cancer. 10 Let-7 miRNAs function as a tumor suppressor through regulation of key oncogenes, including MYC and RAS, by binding specific sites in the mRNA 3'-untranslated regions and inhibiting translation of these targets. 11, 12 Low expression of let-7 family members is associated with poor prognosis in several cancer types. 13, 14 In humans, let-7 g and let-7i are located individually on chromosomes 3 and 12, respectively. The remaining let-7 family members are distributed among six miRNA clusters at genetically distinct loci. The let-7a2 and let-7c clusters are involved in hematopoietic stem and progenitor cell homeostasis by regulating the balance between tumor growth factor-β and Wnt signaling, 15 whereas the let-7e cluster is highly expressed in hematopoietic stem and progenitor cell and confers hematopoietic phenotypes. 16 However, the exact role of the various let-7 family members in mammalian development has not yet been fully elucidated, 17, 18 in large part because it is technically difficult to knock out (KO) multiple let-7 family members in the same individual cell. Moreover, these multiple let-7 family members are likely to have functionally similar roles.
LIN28B is an RNA-binding protein highly expressed in stem cells and developing tissues where it impairs the processing of let-7 precursors into mature, functional miRNAs. 19 Overexpression of LIN28B has been reported in several cancers 20 and is associated with advanced disease and poor outcome in ovarian, 14 breast, 21 colon, 22 hepatocellular carcinoma 23, 24 and neuroblastoma. 25, 26 Transgenic LIN28B has been shown to induce multiple tumor types in mice including liver, Wilms, colon and neuroblastoma, all of which solidify its oncogenic role. 24, 25, 27, 28 LIN28B has also been reported to act through a let-7-independent manner, especially via regulation of IGF2. 24 While the LIN28B/let-7 axis has been implicated in the regulation of MYC in different tumor types, 20 its potential as a therapeutic target has not yet been explored, specifically in blood cancers. In this study, we define the mechanistic activity of the LIN28/let-7 axis in clonal plasma cells and establish a potential therapeutic role of this pathway in targeting MYC in MM, which could lead to significant therapeutic advances in MM and other cancers.
MATERIALS AND METHODS

Cell and primary cells
The MM cell lines MM.1S and RPMI8226 were purchased from ATCC (Manassas, VA, USA); KMS12BM and MOLP-8 were purchased from DSMZ (Braunschweig, Germany) and KMM-1 was purchased from JCRB Cell Bank (Osaka, Japan). The MM.1S GFP + Luc + cell line was generated by retroviral transduction with the pGC-GFP/Luc vector (gift of A Kung, Dana-Farber Cancer Institute, Boston, MA, USA). Cells were authenticated by short tandem repeat DNA profiling. Primary samples were obtained from BM aspiration from both MM patients and healthy controls. Plasma cells were isolated using CD138 + microbead selection (Miltenyi Biotec, Auburn, CA, USA). All patients were diagnosed with active MM at diagnosis or at relapse, based on the criteria of the International Myeloma Working Group. 29 Informed consent was obtained from all patients and healthy volunteers in accordance with the Declaration of Helsinki protocol.
Lentivirus-mediated shRNA silencing
LIN28B short hairpin RNA (shRNA) in lentiviral plasmid (TRCN0000122191 and TRCN0000122599) and control shRNA (SHC216V) were purchased from Sigma-Aldrich (St Louis, MO, USA). For viral production, 293T cells were transfected with lentiviral gag/pol, vesicular stomatitis virus-G and the lentiviral plasmid, at a ratio of 1:0.4:1, using Lipofectamine 2000 (Thermo Fisher Scientific, Waltham, MA, USA). Viral particles were harvested after 24 and 48 h. Two milliliters of viral supernatant were used to infect 1 000 000 cells in the presence of polybrene (8 ng/μl). Infected cells were selected on puromycin antibiotic before subsequent analysis.
Lentivirus-mediated CRISPR silencing
LentiCRISPRv2 (Addgene, Cambridge, MA, USA; plasmid no. 52961) and lentiCRISPR:EGFPsgRNA-1 (no. 51760) were gifts from F Zhang. 30 LIN28B sgRNA were designed using the MIT Optimized CRISPR design tool (http:// crispr.mit.edu). Sequences of sgRNA (single guide RNA) were: 5′-CA TCGACTGGAATATCCAA G-3′ for sgLIN28B no. 1 and 5′-CAGAGCAA ACTATTCATGGA-3′ for sgLIN28B no. 2. Human U6 primer 5′-GAGGG CCTATTTCCCATGATT-3′ was used for validation by Sanger sequencing after cloning. Lentivirus production was processed as above for shRNA lentiviral production.
miRNA mimic transfection
Cell lines were transfected with hsa-let-7b mimic or with a control probe (mirVana miRNA mimic; Thermo Fisher Scientific) at final concentration of 40 nM, using Lipofectamine 2000 according to manufacturer's instructions (Thermo Fisher Scientific). Culture medium was changed to regular medium 24 h after transfection and cells were used for functional assays at 48 h. For the rescue experiment, MOLP-8 sgGFP or sgLIN28B no.1 were transfected with a control probe or a mix of anti-let-7a, b, d and g (mirVana anti-miRNA; Thermo Fisher Scientific) at a final concentration of 40 nM, using X-tremeGENE 9 according to the manufacturer's instructions (Roche, Life Science, Penzberg, Germany).
Quantitative reverse transcription-PCR
Mature miRNA and mRNA expression were analyzed by quantitative reverse transcription-PCR (qRT-PCR) using SYBR green dye on an Applied Biosystems AB7500 Real Time PCR System (Foster City, CA, USA). All PCR reactions were run in triplicate. Ct values were normalized on RNU6B and 18 S, respectively, and relative changes were calculated using the 2 − ΔΔCt. The following primer sequences were used: In vivo studies SCID/bg mice (n = 5 per group) used for xenograft experiments were injected subcutaneously with MOLP-8 cells that were infected with either a LIN28B shRNA or a control shRNA. Tumor volume (measured by caliper) were calculated by the formula: length × width 2 × 0.52. 32 To evaluate the effect of let-7 LNA-GapmeR (locked nucleic acid-GapmeR; containing the sequence 5′-AGGTAGTAGGTTGTGT-3′), SCID/bg mice (n = 5 per group) were intravenously injected with 5 × 10 6 MM.1 S GFP + Luc + cells on day 0; followed by intraperitoneally injections of let-7 (20 mg/kg) or control LNA-GapmeR two times a week starting on day 2. Tumor growth was evaluated by bioluminescence imaging and mice were followed for survival.
RESULTS
Deregulation of LIN28B/let-7 axis in MM We first sought to determine whether LIN28B is deregulated in MM, and therefore analyzed two independent publicly available gene expression profiling data sets containing plasma cells from patients with newly diagnosed MM and healthy control donors. These included GSE24080 and GSE2658, containing 22 normal donor plasma cell samples and 559 plasma cell samples from patients with newly diagnosed patients-both from UAMS-and GSE16558, with 5 normal donor plasma cells and 65 plasma cell samples from patients with newly diagnosed MM. We identified a significant overexpression of LIN28B in MM cells compared with (Figure 1a ). We next sought to determine the prognostic relevance of LIN28B in the survival of patients with MM. We performed Kaplan-Meier analysis on a cohort of 542 patients treated with Total Therapy 2 (GSE2658), and observed that high expression of LIN28B was associated with significantly worse overall survival (P = 0.0075) ( Figure 1b ). Therefore, we explored whether targeting the LIN28B/let-7 axis would have a therapeutically relevant role in MM and silenced LIN28B using two lentiviral shRNA constructs that target the mRNA coding sequence in several LIN28B-expressing MM cell lines: MOLP-8, KMS12BM, RPMI8226 and KMM-1. The shRNAs caused degradation of LIN28B mRNA in all cell lines (Figure 1c ). Moreover, pri-let-7 RNA was not modified as shown for pri-let-7 g, consistent with the post-transcriptional regulation of let-7 by LIN28B ( Supplementary Figure 1a) .
LIN28B regulates let-7 and MYC in MM Consistent with the role of LIN28B in regulating let-7 expression, we observed derepression of let-7 family members in cells with LIN28B knockdown compared with non-targeting control (Figure 2a ). We next analyzed the downstream targets of LIN28B/let-7 and found a decreased protein expression of MYC in LIN28B-silenced cells in several MM cell lines (Figure 2b) . Moreover, knockdown of LIN28B significantly impaired the proliferation of these cell lines tested (Figure 2c ). Consistent with these observations, we identified, through gene set enrichment analysis (GSEA), an enrichment of let-7 target genes in MM patient samples who displayed a high level of LIN28B expression in two independent data sets (GSE2658 and MMRC data set), suggesting that LIN28B represses let-7 and indirectly enriches let-7 target expression ( Figure 3a ).
In addition, among let-7 target genes, MYC expression significantly correlated with LIN28B expression level in two independent data sets (GSE16558 and GSE2658). As shown in Supplementary Figure 1b , a strong correlation existed between LIN28B and MYC in MM tumor cells from patient samples in GSE16558 and in Total Therapy 2 GSE2658, P o0.028 and Po 0.001, respectively.
To validate whether MM cells are dependent on LIN28B for growth, we examined tumor growth of MOLP-8 cell line with a LIN28B-specific hairpin or non-targeting control in a xenograft mouse model using SCID/bg mice. Tumor growth was significantly (Figure 3b ), resulting in a significant prolongation of survival in the experimental group, P = 0.0045 (Figure 3c ). In addition, MYC expression was significantly reduced in cells obtained ex vivo from mice injected with LIN28B knockdown compared with scrambled control (Supplementary Figure 1c) . Taken together, these data suggest a deregulation of LIN28B/let-7 axis in a proportion of patients with MM and can function as a novel therapeutic target of MYC regulation in MM.
MYC and cell cycle pathways are highly enriched in cells with high expression of LIN28B. To control for possible off-target effect of shRNAs and for incomplete LIN28B knockdown mitigating the observed phenotype, we next used CRISPR/Cas9 technology to KO LIN28B in the MOLP-8 cell line. sgRNAs targeting exons 2 and 3 of LIN28B were used ( Supplementary Figure 2a ). Significant decrease in LIN28B protein levels were observed, indicating high-frequency LIN28B KO in the cell population. MYC protein levels were similarly decreased (Figure 4a ). Moreover, LIN28B KO resulted in derepression of let-7, which was consistent with the shRNA experiment ( Figure 4b ). Moreover, LIN28B KO led to the reduced proliferation by thymidine uptake assay (Figure 4c ).
For further characterization of the LIN28B/let-7 axis in MM, we performed RNA-sequencing of the LIN28B CRISPR-KO cells and GFP sgRNA control cells in triplicate. LIN28B was confirmed to be the most significantly downregulated gene in LIN28B-silenced cells (Figure 5a ), confirming efficient KO. We then queried the top 150 downregulated genes in LIN28B KO cells against the MSigDB 'H' hallmark, 'c2' canonical pathways and 'c3' transcription factor target gene sets. The 10 most enriched gene sets were present in E2F cell cycle pathway regulation (Figure 5b ). Of note, E2F2, a let-7 target gene, was one of the most downregulated genes in LIN28B KO cells. Moreover, we found a significant enrichment of let-7 target genes in control compared with LIN28B KO cells (Figure 6a ). Using an unsupervised GSEA analysis of the whole data set against the MSigDB 'H' hallmark gene sets, we found that the MYC pathway gene set was in the top five genes sets, which further suggests that the LIN28B/let-7 axis regulates MYC in MM. Moreover, significant enrichment of MYC pathway in control cells was a b (Figure 6b) .
These results support a model where LIN28B represses let-7, thereby enriching let-7 targets such as E2F2 and MYC in MM.
Given that LIN28B has been reported to act both in a let-7dependent and -independent manner, 33 we next asked whether the functional role of LIN28B is mediated via let-7 in MM. We thus performed a rescue experiment by transfection of a let-7 inhibitor into LIN28B KO MOLP-8 cells. We observed a significant decrease of let-7 family members in LIN28B KO cells plus the anti-let-7 (Figure 6c ). Let-7 inhibition also significantly rescued cell proliferation ( Supplementary Figure 2b) , indicating that let-7 is likely the main target of direct regulation by LIN28B, in let-7dependent manner in MM.
Deregulation of let-7 in MM
Given that we demonstrated that LIN28B regulates MM proliferation through let-7, we sought to define the direct role of let-7 in MM. We first assessed the expression level of let-7 family members in primary BM MM CD138 + cells compared with healthy control CD138 + BM plasma cells by qRT-PCR. Let-7 miRNAs were lower in plasma cells from six patients with relapsed MM and in four MM cell lines, as compared with plasma cells from three healthy donors (Figure 7a ). To determine whether let-7 directly regulates MYC in MM, we transfected a let-7b mimic into MM.1S cells ( Supplementary   Figure 3a) and observed a reduction of cell proliferation (Figure 7b ) as well as a decrease level of MYC protein (Supplementary Figure 3b) . To validate these findings in patient samples, we assessed the correlation between let-7 and MYC expressions in publicly available gene expression profiling with matched miRNA array from MM patients (GSE16558). We found a significant inverse correlation between expression of let-7b and g and the expression level of MYC in a cohort of 60 patients (Figure 7c ). These data support the idea that LIN28B acts in a let-7-dependent manner in MM and suggest that low expression levels of let-7 in MM patients contributes to MYC dysregulation and tumor proliferation.
Let-7 as a potential therapeutic target that regulates MYC in MM We next sought to confirm the importance of let-7 in MM in vivo and to assess whether let-7 could serve as a therapeutic strategy to target directly MYC in MM. We therefore developed a let-7 LNA-GapmeR mimic, which was designed based on the seed region of let-7 miRNAs to mark efficiently let-7 target genes for degradation by RNAse H. We first tested the ability of the let-7 LNA-GapmeR to decrease let-7 target genes in vitro. MM.1S cell line was cultured in the presence of a control probe or three different concentrations of let-7 LNA-GapmeR (10 nM, 100 nM and 1 μM). By qRT-PCR we observed a consistent decrease of MYC, KRAS, CCND1, E2F6, DICER1 and HMGA1 expression levels in parallel to increased concentration of the GapmeR (Supplementary Figure 4a) . We next tested the let-7 LNA-GapmeR in vivo in a xenograft mouse model. SCID/bg mice were injected with 5 × 10 6 MM.1S GFP + Luc + cells intravenously, followed by intraperitoneal injections of let-7 LNA-GapmeR two times a week. The treatment was well tolerated and did not induce obvious toxicity or weight loss. The tumor growth was evaluated by bioluminescence imaging, and was significantly reduced in the group of mice that received let-7 LNA-GapmeR as compared with the control group, P = 0.018 (Figure 8a and Supplementary Figure 4b ). This was associated with consequent significant survival benefit, P = 0.026 (Figure 8b ). Ex vivo, MM cells were analyzed for MYC expression, confirming the repression of MYC in the let-7 LNA-GapmeR group (Figure 8c ). This experiment provides proof of principle that let-7 could represent a new therapeutic approach targeting MYC in MM.
DISCUSSION
In this study, we describe the role of the LIN28B/let-7 axis in MM and identify let-7 as a potential new therapeutic approach for targeting MYC. High expression of LIN28B in MM is associated with both adverse outcomes and MYC overexpression. LIN28B represses let-7 expression in MM cells, resulting in deregulation of MYC protein and cell proliferation in vitro and in vivo. A pathway enrichment analysis in LIN28B KO cells reveals the importance of the MYC and E2F cell cycle pathways within the LIN28B/let-7 axis. Moreover, LIN28B-induced proliferation and MYC deregulation is let-7 dependent. The tumor growth impairment in vivo by administration of a let-7b based LNA-GapmeR provides proof of principle for a new therapeutic option to target MYC in MM (Supplementary Figure 5) .
Let-7 miRNAs have been described as tumor suppressor in several cancers, by targeting major oncogenic pathways. 9 Copy number loss [34] [35] [36] or epigenetic silencing 37 of individual let-7 family members has been reported in some cancers. In MM, several let-7 genes are located in frequently deleted regions, such as let-7g at 3p21, let-7i at 12q14 or let-7a-2 at 11q24. These copy number aberrations might participate in deregulation of the LIN28B/let-7 axis in MM. Here we have described a mechanism of regulation of let-7 miRNAs in MM involving LIN28B, which inhibits let-7 miRNAs, resulting in deregulation of the MYC and E2F cell cycle pathways. Although LIN28B has been reported in liver cancer to act through both let-7-dependent and -independent manners, 24 our findings suggest the predominance of a let-7dependent mechanism in MM.
LIN28B is located in the 6q21 cytogenetic band, which is amplified in some cases of neuroblastoma, resulting in LIN28B overexpression. 25 In MM, previously published Comparative genomic hybridization array did not find amplification at 6q21 locus. 38 The increased expression of LIN28B might therefore result from epigenetic changes such as altered methylation or histone modification or deregulation of upstream processes. MiR-125b was reported to inhibit LIN28B in embryonic stem cells as well as in some case of cancers. 25, 39, 40 Interestingly, miR-125b is located in 11q23, which is frequently deleted in MM. Of note, let-7 miRNAs themselves have also been reported to regulate LIN28B expression, in a feedback loop manner. 41 Moreover, a recent report suggests that inactivation of DIS3 increases LIN28B expression in MM, 42 by impairing its mRNA degradation. DIS3 is an exosome endoribonuclease involved in the turnover and degradation of mRNA in the cytoplasm. Strikingly, DIS3 is one of the most frequently mutated genes in MM, 43, 44 further suggesting a central role for LIN28B/let-7 axis in MM.
Despite the key roles for MYC in MM, there are very few therapeutic options targeting MYC. Previous studies attempted to target MYC by using a bromodomain inhibitor to target BET proteins, which regulate MYC. 6, 7 The clinical impact of these inhibitors is being elucidated in early phase clinical trials with some potentially promising results in hematological malignancies. Our findings provide proof of principle that therapeutic use of let-7 can allow the repression of multiple oncogenes concurrently in MM. We show that in vivo use of let-7 effectively regulates MYC, which is an essential regulator of tumor progression in MM and other cancers. Our findings indicate the importance of let-7 regulation in MM and suggest that let-7 may be an effective therapeutic option that can directly target MYC in MM. 
